There are no absolute contraindications listed for tazemetostat. However, it should be used with caution in certain situations:

Pregnant women should not take tazemetostat, as it can cause harm to an unborn baby. Effective non-hormonal contraception is recommended for women of childbearing potential during treatment and for 6 months after the last dose. Men with female partners of reproductive potential should also use contraception during treatment and for 3 months after the last dose.
Women should not breastfeed during treatment and for at least 1 week after the final dose.
Patients with a history of secondary cancers should discuss the risks with their doctor, as tazemetostat can increase the risk of developing other blood cancers.

Always inform your healthcare provider about all your medical conditions and medications before starting tazemetostat.